Header Logo

Connection

THOMAS KOSTEN to Schizophrenic Psychology

Back to Details
This is a "connection" page, showing publications THOMAS KOSTEN has written about Schizophrenic Psychology.
THOMAS KOSTEN
Connection Strength
5.572
Schizophrenic Psychology
  1. Smoking reduction and quality of life in chronic patients with schizophrenia in a Chinese population--A pilot study. Am J Addict. 2016 Mar; 25(2):86-90.
    View in: PubMed
    Score: 0.474
  2. Socio-demographic and clinical characteristics of heavy and non-heavy smokers among schizophrenia inpatients in a Chinese Han population. Psychopharmacology (Berl). 2014 Jan; 231(1):305-14.
    View in: PubMed
    Score: 0.400
  3. Prevalence, demographic and clinical correlates of suicide attempts in Chinese medicated chronic inpatients with schizophrenia. J Psychiatr Res. 2013 Oct; 47(10):1370-5.
    View in: PubMed
    Score: 0.395
  4. Cognitive function, plasma MnSOD activity, and MnSOD Ala-9Val polymorphism in patients with schizophrenia and normal controls. Schizophr Bull. 2014 May; 40(3):592-601.
    View in: PubMed
    Score: 0.391
  5. Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia. Am J Psychiatry. 2012 Sep; 169(9):974-81.
    View in: PubMed
    Score: 0.374
  6. Association of functional dopamine-beta-hydroxylase (DBH) 19 bp insertion/deletion polymorphism with smoking severity in male schizophrenic smokers. Schizophr Res. 2012 Oct; 141(1):48-53.
    View in: PubMed
    Score: 0.372
  7. Gender differences in never-medicated first-episode schizophrenia and medicated chronic schizophrenia patients. J Clin Psychiatry. 2012 Jul; 73(7):1025-33.
    View in: PubMed
    Score: 0.370
  8. Cigarette smoking and cognitive function in Chinese male schizophrenia: a case-control study. PLoS One. 2012; 7(5):e36563.
    View in: PubMed
    Score: 0.366
  9. Plasma total antioxidant status and cognitive impairments in schizophrenia. Schizophr Res. 2012 Aug; 139(1-3):66-72.
    View in: PubMed
    Score: 0.366
  10. Cigarette smoking in male patients with chronic schizophrenia in a Chinese population: prevalence and relationship to clinical phenotypes. PLoS One. 2012; 7(2):e30937.
    View in: PubMed
    Score: 0.360
  11. Nicotine dependence, symptoms and oxidative stress in male patients with schizophrenia. Neuropsychopharmacology. 2007 Sep; 32(9):2020-4.
    View in: PubMed
    Score: 0.253
  12. Cognitive Deficits and Clinical Symptoms with Hippocampal Subfields in First-Episode and Never-Treated Patients with Schizophrenia. Cereb Cortex. 2021 01 01; 31(1):89-96.
    View in: PubMed
    Score: 0.167
  13. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry. 2000 Nov; 157(11):1835-42.
    View in: PubMed
    Score: 0.165
  14. Minocycline adjunctive treatment to risperidone for negative symptoms in schizophrenia: Association with pro-inflammatory cytokine levels. Prog Neuropsychopharmacol Biol Psychiatry. 2018 07 13; 85:69-76.
    View in: PubMed
    Score: 0.138
  15. Smoking and Serum Lipid Profiles in Schizophrenia. Neurosci Bull. 2016 Aug; 32(4):383-8.
    View in: PubMed
    Score: 0.120
  16. Tardive dyskinesia is associated with greater cognitive impairment in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2013 Oct 01; 46:71-7.
    View in: PubMed
    Score: 0.099
  17. Diabetes and cognitive deficits in chronic schizophrenia: a case-control study. PLoS One. 2013; 8(6):e66299.
    View in: PubMed
    Score: 0.099
  18. Interleukin 18 and cognitive impairment in first episode and drug na?ve schizophrenia versus healthy controls. Brain Behav Immun. 2013 Aug; 32:105-11.
    View in: PubMed
    Score: 0.097
  19. Thioredoxin, a novel oxidative stress marker and cognitive performance in chronic and medicated schizophrenia versus healthy controls. Schizophr Res. 2013 Feb; 143(2-3):301-6.
    View in: PubMed
    Score: 0.095
  20. Gender differences in cognitive function of patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2012 Dec 03; 39(2):358-63.
    View in: PubMed
    Score: 0.093
  21. Elevated interleukin-18 serum levels in chronic schizophrenia: Association with psychopathology. J Psychiatr Res. 2012 Aug; 46(8):1093-8.
    View in: PubMed
    Score: 0.092
  22. Association of catechol-O-methyltransferase gene polymorphisms with schizophrenia and negative symptoms in a Chinese population. Am J Med Genet B Neuropsychiatr Genet. 2012 Jun; 159B(4):370-5.
    View in: PubMed
    Score: 0.090
  23. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry. 2002 Jul 01; 52(1):53-61.
    View in: PubMed
    Score: 0.046
  24. Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology. 2002 Jan; 26(1):75-85.
    View in: PubMed
    Score: 0.045
  25. Nicotine dependence and schizophrenia. Hosp Community Psychiatry. 1994 Mar; 45(3):204-6.
    View in: PubMed
    Score: 0.026
  26. Treatment of dual diagnosis patients: a relapse prevention group approach. J Subst Abuse Treat. 1992; 9(4):305-9.
    View in: PubMed
    Score: 0.022
  27. Reduced plasma total antioxidant status in first-episode drug-naive patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 01; 35(4):1064-7.
    View in: PubMed
    Score: 0.021
  28. Decreased levels of serum brain-derived neurotrophic factor in drug-na?ve first-episode schizophrenia: relationship to clinical phenotypes. Psychopharmacology (Berl). 2009 Dec; 207(3):375-80.
    View in: PubMed
    Score: 0.019
  29. Altered interleukin-3 serum levels in drug-na?ve and neuroleptic-treated schizophrenic patients. Schizophr Res. 2008 Dec; 106(2-3):369-70.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.